Skip to content

Impact of different breathing patterns on autonomic nervous system function in patients with right-ventricular or left-ventricular dysfunction or with normal cardiac function

Impact of different breathing patterns on autonomic nervous system function in patients with right-ventricular or left-ventricular dysfunction or with normal cardiac function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00013659
Enrollment
60
Registered
2018-03-15
Start date
2018-04-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50.1 I50.0

Interventions

Group 1: In 20 well-characterised patients with Nizza class I pulmonary arterial hypertension (PAH) continuous measurement of muscular sympathetic nerve activity (MSNA) and non invasive hemodynamic mo

Sponsors

Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: a. Age > 18 years (no age limit) (Group 1, 2 and 3) b. able to consent (Group 1, 2 and 3) c. Diagnosis of Nizza class I pumonary arterial Hypertension -PAH- and heart failure with reduced ejection fraction -HFrEF- according to the most recent Guidelines of the European Society of Cardiology (ESC); >12 weeks since the diagnosis of HFrEF / PAH has been made; no hospitalisation for HF in the last 4 weeks; optimal medical therapy in accordance with the most recent Guidelines of the European Society of Cardiology (ESC) with no change in medication in the last 4 weeks and combination therapy for both PAH and HFrEF -where there was no treatment with combination therapy in PAH patients or with beta blockers or ACE Inhibitors/ARBs in HFrEF, then the reason must be documented) d. healthy controls (matched for age and gender) with normal findings on echocardiogram, electrocardiogram and normal levels of natriuretic peptide hormone (Group 3)

Exclusion criteria

Exclusion criteria: - other severe internistic pre-existing conditions, especially insulin-dependent diabetes or severe renal impairment - severe neurological pre-existing conditions such as stroke, especially brainstem infarction - intake of opioids - psychiatric pre-existing conditions

Design outcomes

Primary

MeasureTime frame
Muscular sympathetic nerve activity [Burst rate/min; Burst rate/100 beats; measured through a microneurography device produced by AD Instruments with a small needle inserted in the peroneal nerve], high frequency component of heart rate variability [%; measured through a non-invasive hemodynamic Monitor -Task Force Monitor- produced by CNSystems], low frequency component of diastolic blood pressure variability [%; measured through a non-invasive hemodynamic Monitor -Task Force Monitor- produced by CNSystems]

Secondary

MeasureTime frame
Heart rate [bpm], systolic blood pressure [mmHG], diastolic blood pressure [mmHG], stroke volume index [L/min/m²], high frequency component of diastolic blood pressure variability[%], low frequency component of heart rate variability [%], -> the above mentioned will be measured through a non-invasive hemodynamic Monitor -Task Force Monitor- produced by CNSystems respiratory rate [/min], tidal volume [ml], minute ventilation [L/min], oxygen saturation [%], transcutaneous CO2 [mmHG] -> the above mentioned will be measured through a polysomnography device produced by Nihon Kohden ->mean values under the different interventions will be obtained and compared

Countries

Germany

Contacts

Public ContactJens Spiesshoefer

Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster

jens.spiesshoefer@ukmuenster.de00492518341119

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026